Certara reports Q3 adjusted EPS 14c, consensus 11c

Reports Q3 revenue $104.6M, consensus $104.57M. “In the third quarter, we continued to make good progress towards our full-year revenue and profitability targets,” said William Feehery, CEO. “We recently launched several new software products, including Certara (CERT)IQ for QSP modeling, which we believe will expand the use of biosimulation technology in drug development. We remain focused on investing in our R&D and commercial efforts to position Certara for sustainable, long-term growth.”